AU2012292024A1 - Mutations in the epidermal growth factor receptor gene - Google Patents

Mutations in the epidermal growth factor receptor gene Download PDF

Info

Publication number
AU2012292024A1
AU2012292024A1 AU2012292024A AU2012292024A AU2012292024A1 AU 2012292024 A1 AU2012292024 A1 AU 2012292024A1 AU 2012292024 A AU2012292024 A AU 2012292024A AU 2012292024 A AU2012292024 A AU 2012292024A AU 2012292024 A1 AU2012292024 A1 AU 2012292024A1
Authority
AU
Australia
Prior art keywords
egfr
seq
cetuximab
cancer
panitumumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012292024A
Other languages
English (en)
Inventor
Joan Albanell Mestres
Beatriz Bellosillo Paricio
Alba Dalmases Massegu
Clara Montagut Viladot
Ana Rovira Guerin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundació Institut Hospital del Mar d'Investigacions Mèdiques
Original Assignee
Fundació Institut Hospital del Mar d'Investigacions Mèdiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Institut Hospital del Mar d'Investigacions Mèdiques filed Critical Fundació Institut Hospital del Mar d'Investigacions Mèdiques
Publication of AU2012292024A1 publication Critical patent/AU2012292024A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2012292024A 2011-08-03 2012-08-02 Mutations in the epidermal growth factor receptor gene Abandoned AU2012292024A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382270A EP2554551A1 (en) 2011-08-03 2011-08-03 Mutations in the epidermal growth factor receptor gene
EP11382270.4 2011-08-03
PCT/EP2012/065090 WO2013017645A1 (en) 2011-08-03 2012-08-02 Mutations in the epidermal growth factor receptor gene

Publications (1)

Publication Number Publication Date
AU2012292024A1 true AU2012292024A1 (en) 2014-02-27

Family

ID=46640020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012292024A Abandoned AU2012292024A1 (en) 2011-08-03 2012-08-02 Mutations in the epidermal growth factor receptor gene

Country Status (12)

Country Link
US (1) US9765399B2 (cg-RX-API-DMAC7.html)
EP (3) EP2554551A1 (cg-RX-API-DMAC7.html)
JP (1) JP6149034B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140072035A (cg-RX-API-DMAC7.html)
CN (1) CN103717616B (cg-RX-API-DMAC7.html)
AU (1) AU2012292024A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014002373A2 (cg-RX-API-DMAC7.html)
CA (1) CA2842270C (cg-RX-API-DMAC7.html)
ES (1) ES2556468T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN00570A (cg-RX-API-DMAC7.html)
RU (1) RU2014107908A (cg-RX-API-DMAC7.html)
WO (1) WO2013017645A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2015175705A1 (en) 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Gene mutations and copy number alterations of egfr, kras and met
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
JP6905464B2 (ja) * 2014-07-28 2021-07-21 フンダシオ インスティトゥ マー ディンヴェスティガシオンズ メディクー(イーエメイーエメ) 上皮増殖因子受容体遺伝子の細胞外ドメインiii内の変異
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
EP3286219A1 (en) * 2015-04-24 2018-02-28 Merrimack Pharmaceuticals, Inc. Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies
RU2626682C1 (ru) * 2016-07-20 2017-07-31 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования резистентности опухоли к таргетной терапии цетуксимабом у больных плоскоклеточным раком языка и слизистой дна полости рта
CN111499749B (zh) * 2020-03-13 2021-11-09 浙江大学 一种西妥昔单抗突变体及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558753A1 (en) 2004-03-01 2005-09-15 University Of Chicago Polymorphisms in the epidermal growth factor receptor gene promoter
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
CA2601936C (en) * 2005-02-24 2014-06-17 Amgen Inc. Epidermal growth factor receptor mutations
CN1737162A (zh) * 2005-03-16 2006-02-22 南京中医药大学附属医院(江苏省中医院) 表皮生长因子受体(egfr)基因测序检测方法
US7981606B2 (en) * 2005-12-21 2011-07-19 Roche Molecular Systems, Inc. Control for nucleic acid testing
JP5596975B2 (ja) * 2006-10-26 2014-10-01 ジェネンテック, インコーポレイテッド 腫瘍と関連している遺伝的変異
CA2675362A1 (en) 2007-01-18 2008-07-24 University Of Southern California Polymorphisms in the egfr pathway as markers for cancer treatment
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
EP3216874A1 (en) * 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options

Also Published As

Publication number Publication date
BR112014002373A2 (pt) 2017-02-21
CA2842270A1 (en) 2013-02-07
RU2014107908A (ru) 2015-09-10
EP2554551A1 (en) 2013-02-06
WO2013017645A1 (en) 2013-02-07
JP2014521342A (ja) 2014-08-28
KR20140072035A (ko) 2014-06-12
EP2739648A1 (en) 2014-06-11
US9765399B2 (en) 2017-09-19
US20140170662A1 (en) 2014-06-19
CN103717616A (zh) 2014-04-09
JP6149034B2 (ja) 2017-06-14
EP2739648B1 (en) 2015-09-16
CN103717616B (zh) 2016-06-29
ES2556468T3 (es) 2016-01-18
EP2995623A1 (en) 2016-03-16
CA2842270C (en) 2019-10-29
IN2014CN00570A (cg-RX-API-DMAC7.html) 2015-04-03

Similar Documents

Publication Publication Date Title
CA2842270C (en) Mutations in the epidermal growth factor receptor gene
CN107794302B (zh) 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
Lee et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
CN102216775B (zh) 对hsp90-抑制剂的易感性
TW201902509A (zh) Erbb2/her2突變
US20210262037A1 (en) Methods of treating cancer based on identifying mutations in the extracellular domain iii of epidermal growth factor receptor gene
EP2542692A1 (en) Method for selecting patients for treatment with an egfr inhibitor
HK1252399B (en) Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
Franzi Immunohistochemical expression and molecular analysis of epidermal growth factor receptor mutations in lung adenocarcinoma.
HK1212397B (en) Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
HK1208250B (en) Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
HK1133045A (en) Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted